Relationship Between Growth Differentiation Factor-15 Levels and Micro-Atrial Fibrillation
Open Access
- 1 June 2026
- journal article
- Published by The European Research Journal in The European Research Journal
- p. 616-622
Abstract
Objective: Micro-atrial fibrillation (micro-AF) represents short, irregular supraventricular tachyarrhythmia episodes that may precede clinical atrial fibrillation (AF). Identifying biomarkers associated with micro-AF could improve early detection and risk stratification. Growth Differentiation Factor-15 (GDF-15), a stress-responsive cytokine related to inflammation and myocardial injury, has been associated with AF, but its relationship with micro-AF remains unclear. Methods: Ninety patients who underwent 24-hour Holter monitoring due to palpitations were enrolled. Forty-five patients with micro-AF and 45 controls without supraventricular tachyarrhythmia were compared. Serum GDF-15 levels and clinical characteristics were analyzed using standard statistical methods, including logistic regression analysis and Receiver Operating Characteristic (ROC) curve analyses. Results: The groups were similar in age, sex, and comorbidities. Prior stroke was significantly more frequent in the micro-AF group (28.8% vs. 6.7%, P<0.001). Mean serum GDF-15 levels were significantly higher in patients with micro-AF than in controls (544.2±322.5 vs. 344±138.8 pg/mL, P<0.001). Logistic regression revealed that GDF-15 was associated with stroke risk in univariate analysis but not independently in multivariate analysis. Conclusion: Elevated GDF-15 levels in individuals with micro-AF suggest an underlying inflammatory or structural atrial substrate, supporting its potential role as a biomarker for early arrhythmia detection and assessment of thromboembolic risk. Larger, prospective studies are warranted to clarify the prognostic significance of GDF-15 in micro-AF.Keywords
This publication has 16 references indexed in Scilit:
- Global burden of atrial fibrillation/atrial flutter and its attributable risk factors from 1990 to 2021EP Europace, 2024
- Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state modelAmerican Heart Journal, 2022
- Increased plasma levels of NT-proBNP, Troponin T and GDF-15 are driven by persistent AF and associated comorbidities: Data from the AF-RISK studyIJC Heart & Vasculature, 2022
- Excessive Supraventricular Ectopic Activity and Adverse Cardiovascular Outcomes: a Systematic Review and Meta-analysisCurrent Atherosclerosis Reports, 2020
- Growth differentiation factor-15 and all-cause mortality in patients with suspected myocardial infarctionInternational Journal of Cardiology, 2019
- Atrial Fibrillation Burden: Moving Beyond Atrial Fibrillation as a Binary Entity: A Scientific Statement From the American Heart AssociationCirculation, 2018
- The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillationEuropean Heart Journal, 2016
- Response to Letter Regarding Article, “Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy”Circulation, 2013
- Prognostic Value of Growth-Differentiation Factor-15 in Patients With Non–ST-Elevation Acute Coronary SyndromeCirculation, 2007
- The Transforming Growth Factor-β Superfamily Member Growth-Differentiation Factor-15 Protects the Heart From Ischemia/Reperfusion InjuryCirculation Research, 2006